Proxi Biotech was founded in 2018, based on research conducted at the Statens Serum Institute in Denmark, with a mission to provide innovative active immunotherapy to help patients and healthcare systems overcome the clinical burden of bacterial re-infections caused by drug-resistant pathogens.

Our research and technology are led by world-class scientists with a strong passion and track record of turning lab scale research into effective vaccine products.  

READ ABOUT THE TEAM

Proxi Biotech's platform is a versatile toxoid antigen technology developed to create and advance novel immunotherapies against high-priority diseases. We focus on developing and bringing therapeutic  candidates through preclinical proof-of-concept in relevant animal models and advancing into early clinical phase. 

We have received numerous national and European non-dilutive grants and funding for a total of ca. 1.800.000 EUR

PRESS COVERAGE & INTERNATIONAL AWARDS